| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/08/2023 | 572.49% | Cantor Fitzgerald | → $5 | Initiates Coverage On | → Overweight |
| 09/17/2020 | 841.49% | Ascendiant Capital | → $7 | Initiates Coverage On | → Buy |
| 12/18/2019 | — | Maxim Group | Upgrades | Hold → Buy |
What is the target price for Atossa Therapeutics (ATOS)?
The latest price target for Atossa Therapeutics (NASDAQ: ATOS) was reported by Cantor Fitzgerald on September 8, 2023. The analyst firm set a price target for $5.00 expecting ATOS to rise to within 12 months (a possible 572.49% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Atossa Therapeutics (ATOS)?
The latest analyst rating for Atossa Therapeutics (NASDAQ: ATOS) was provided by Cantor Fitzgerald, and Atossa Therapeutics initiated their overweight rating.
When is the next analyst rating going to be posted or updated for Atossa Therapeutics (ATOS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atossa Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atossa Therapeutics was filed on September 8, 2023 so you should expect the next rating to be made available sometime around September 8, 2024.
Is the Analyst Rating Atossa Therapeutics (ATOS) correct?
While ratings are subjective and will change, the latest Atossa Therapeutics (ATOS) rating was a initiated with a price target of $0.00 to $5.00. The current price Atossa Therapeutics (ATOS) is trading at is $0.74, which is within the analyst's predicted range.